Compare · AMPX vs TMO
AMPX vs TMO
Side-by-side comparison of Amprius Technologies Inc. (AMPX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- AMPX operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 209.9x AMPX ($1.23B).
- Over the past year, AMPX is down 34.8% and TMO is up 28.0% - TMO leads by 62.8 points.
- TMO has been more active in the news (7 items in the past 4 weeks vs 5 for AMPX).
- TMO has more recent analyst coverage (25 ratings vs 10 for AMPX).
- Company
- Amprius Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $7.71-8.32%
- $690.13-0.92%
- Market cap
- $1.23B
- $257.53B
- 1M return
- -19.06%
- +4.77%
- 1Y return
- -34.80%
- +28.01%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 5
- 7
- Recent ratings
- 10
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest AMPX
- Canaccord Genuity initiated coverage on Amprius Technologies with a new price target
- SEC Form S-3ASR filed by Amprius Technologies Inc.
- CAMINUS Signs Contract Manufacturing Agreement with Amprius Technologies for U.S. Pouch Cell Production
- Amprius Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Amprius Secures $75 Million Grant for American High-Energy Density Battery Production
- Amprius Introduces SiCore®500 – High Energy Density Cells for Unmanned Aviation
- Amprius Sets September 2026 Events Schedule
- SEC Form 144 filed by Amprius Technologies Inc.
- Director Sun Kang sold $642,186 worth of shares (62,101 units at $10.34), decreasing direct ownership by 5% to 1,218,397 units (SEC Form 4) to satisfy tax liability
- Chief Technology Officer Stefan Constantin Ionel sold $306,931 worth of shares (29,681 units at $10.34), decreasing direct ownership by 4% to 771,629 units (SEC Form 4) (withholding obligation)
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)